Proteolytic degradation products of fibrinogen, produced as a result of excessive fibrinolysis, have been demonstrated in the blood of cirrhotic patients. 7,8 Such degradation products, when formed in ...

Bleeding because of impaired platelet function is a major side effect of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib. We quantitatively assessed ristocetin-induced platelet aggregation ...

Approximately 40% of adolescent women experience heavy menstrual bleeding (HMB), and 10–62% of them have an underlying bleeding disorder (BD). Diagnosing a BD remains challenging because of ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

Prasugrel provided a more rapid reduction in platelet aggregation than clopidogrel in patients with stable coronary artery disease on dual antiplatelet therapy and an impaired renal function, ...

Researchers have identified serine threonine kinase 10 as a key regulator of platelet function, haemostasis and ...

Patients on prasugrel therapy have greater platelet inhibition than those taking maintenance doses of clopidogrel and thus require a longer time to return to baseline reactivity after stopping the ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

Managing drug dosage is critical to the overall success of pharmaceutical intervention, not only in the clinic but also in clinical trials. Inadequate dose management of certain drugs can have fatal ...

Abstract and Introduction Review of Normal Platelet Physiology and Megakaryocytopoisis Qualitative Platelet Abnormalities Conclusion References Nitric oxide (NO) is another drug used in the neonatal ...

DUBLIN--(BUSINESS WIRE)--The "Global Platelet Aggregation Devices Market - Segmented by Product (Systems, Reagents, Consumables and Accessories), Application, End User and Geography - Growth, Trends ...

Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8% ...